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ABSTRACT
Background: Single inhaled corticosteroids and long-acting beta-agonists (ICSLABA) are clinically effective
and safe. However, if local oropharyngeal and laryngeal adverse effects (LOLAE) appear, adherence to the use
of ICS is impaired. To minimize the development of adverse effects, it is essential to identify the underlying risk
factors.
Methods: The study included 481 asthmatic patients who were prescribed ICSLABA for the first time in their
life between January and September of 2010. Patients ranged in age from 14 to 86 years old and consisted of
281 never smokers and 200 smokers. All data were collected retrospectively by respirologists.
Results: Seventy-three out of 481 patients suffered from one or more adverse effects, with 54 of these exhibit-
ing LOLAE. Patients with LOLAE (51.4 ± 16.2 yrs) were significantly older than those without LOLAE (43.7 ±
15.9 yrs) (p = 0.0011) and were also prescribed a significantly higher dose of ICS. The pack-years of patients
with LOLAE (2.1 ± 4.9) were significantly lower than those without LOLAE (6.0 ± 13.0) (p = 0.0087). The type of
administered ICS was also significantly associated with a risk of developing LOLAE.
Conclusions: Our survey indicated that a greater age, a higher dose of ICS, and the type of ICS were poten-
tial risk factors of LOLAE. The identified factors should be considered in a clinical setting in order to prevent the
development of LOLAE and provide optimal treatment to patients.
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INTRODUCTION
Asthma is a serious worldwide public health problem
for all age groups and is characterized by chronic air-
way inflammation, which is associated with airway hy-
persensitiveness. Although the clinical manifestations
of asthma can be controlled with appropriate treat-
ment, if asthma is not treated properly, airway inflam-
mation worsens, resulting in remodeling of the air-
way and irreversible airflow limitation. Corticoster-
oids are the most effective anti-inflammatory medica-
tion for bronchial asthma.1 Notably, smaller amounts
of inhaled corticosteroids (ICS) show clinical efficacy
for asthma than that needed for oral corticosteroids;
for example, it has been reported that 600 μg of
budesonide (BUD) is equivalent to 10 mg of predni-
solone (PSL).2 The introduction of ICS has markedly
reduced hospitalizations3 and death from asthma.4
Further progress in asthma treatment has been
achieved by the introduction of a combination ther-
apy with ICS and long-acting beta-agonists (LABA).
Such a combination therapy is considered beneficial
for patients who have persistent asthma symptoms
despite treatment with ICS.5-7 Single-inhaler therapy
with combined ICSLABA is considered more clini-
cally effective and well-tolerated than separate inhaler
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Table　1　Patient characteristics
n (%)
Male 206 (42.8%)
Female 275 (57.2%)
Smoking history
Never Smokers 281 (58.4%)
Ex-Smokers and Current Smokers 200 (41.6%)
Mild Smokers (<20 pack year) 154 (32.0%)
Heavy Smokers (>=20 pack year) 46 ( 9.6%)
Pack-year (including Never Smokers) 5.59 ±12.4
Bronchial asthma 274 (57.0%)
Cough variant asthma 207 (43.0%)
Duration since diagnosis (yr) 4.5 ±9.7
Any previous treatment for asthma 169 (35.1%)
Type of ICS/LABA
Budesonide/Formoterol 143 (29.7%)
Fluticasone/Salmeterol 338 (70.3%)
Daily dose of ICS (μg of fl uticasone) 677 ±320
Concomitant treatment
Any one of the following 309 (64.2%)
Oral corticosteroid 162 (33.7%)
Leukotriene receptor antagonist 151 (31.4%)
Theophylline 157 (32.6%)
Short-acting β-agonist 63 (13.1%)
ICS/LABA, single inhaled corticosteroids and long-acting beta 
agonists; Daily dose of ICS (μg of fl uticasone), budesonide dose 
was converted to half the dose of fl uticasone.
therapy.8,9 The main advantages of single-inhaler
therapy are the improvement of adherence,10-12 which
is achieved by a simplified medication regimen, and
patients’ subjective symptomatic benefit following in-
halation administration.
Although single-inhaler therapy with ICSLABA is
generally considered safe, local side effects, including
oral laryngeal infection, hoarseness, and sputum, are
often observed and may adversely influence patients’
adherence.13 Low medication adherence poses seri-
ous risks for asthma exacerbation, hospital admis-
sion, and even death.14 Therefore, minimizing the de-
velopment of adverse effects associated with ICS
LABA is essential for the successful treatment of
asthma patients in a clinical setting. However, suffi-
cient information concerning the potential risk factors
for the adverse effects of ICSLABA is currently un-
available.
The aim of the present study is to identify risk fac-
tors for the adverse effects of ICSLABA to prevent
LOLAE of ICSLABA. Here, we retrospectively ana-
lyzed 481 asthma patients for a variety of factors to
determine their association with the adverse effects
of ICSLABA.
METHODS
PATIENTS
The inclusion criteria for participation in this study
were: (i) being prescribed budesonideformoterol
(BF) or fluticasonesalmeterol (FS) for the first
time in one’s life, (ii) not having been prescribed any
ICS for the previous 12 months, and (iii) visiting the
out-patient department of our hospital at least once
for follow-up during the two months following the in-
itial prescription. Patient lists were obtained from
medical records of the Allergy and Respiratory Medi-
cine Department at the Fraternity Memorial Hospital,
Japan. Patients who were newly prescribed BF or F
S between January and September 2010 were added
to the list. Of the 902 patients included in the list, 387
were excluded for recent ICS prescription, 10 more
were excluded because they did not have asthma,
and 24 others were excluded because they did not
visit for follow-up within the required period. There-
fore, a total of 481 patients were ultimately enrolled in
this study. The mean patient age was 44.5 ± 16.1
years (range: 14 to 86). The smoking status of the pa-
tients was as follows: 281 patients were classified as
never smokers and 200 as current or ex-smokers.
Concerning the diagnosis of asthma, 274 patients had
bronchial asthma (BA) and 207 were diagnosed as
having cough variant asthma (CVA). Detailed patient
characteristics are summarized in Table 1.
STUDY DESIGN
All data were collected retrospectively from medical
records and analyzed by respirologists. Any symp-
toms that satisfied the following criteria were in-
cluded in the analysis: (i) potential adverse effects of
ICSLABA in the opinion of the respirologists, and
(ii) symptoms that occurred in the first two months
following the initial prescription of ICSLABA. Smok-
ers with a smoking history of 20 pack-years or more
were classified as “heavy smokers,” and all others
were classified as “mild smokers.” Spirometry was
performed according to a standard protocol.15 A dose
potency ratio of 2 : 1 (fluticasonebudesonide) was
adopted.16,17 This study was approved by the Institu-
tional Review Board of the Fraternity Memorial Hos-
pital and patient anonymity was preserved at every
stage of the study.
STATISTICS
Mann-Whitney’s U test, Fisher’s exact test, and
Spearman’s correlation coefficient by rank test were
applied to data appropriately. All statistical analyses
were performed using SSRI Excel Toukei 2010 (Japa-
nese version).
RESULTS
Seventy-four out of 481 asthma patients (15%) suf-
fered from one or more adverse effects during the
Risk Factors for Local Adverse Effects of ICSLABA
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Table　2　Adverse effects occurring in asthma patients ad-
ministered ICS/LABA
Adverse effect N
Local oropharyngeal and laryngeal adverse effects 54†
hoarseness 19
laryngopharyngeal discomfort 14
sputum 11
sore throat  5
Candida thrush  4
stomatitis  2
glossitis  2
dysgeusia  2
laryngeal dryness  1
Other adverse effects 20
palpitation  9
tremor  3
nausea  3
rash  2
shoulder stiffness  1
chest pain  1
coughing  1
†Some patients have two or more adverse effects.
Table　3　Risk factors for adverse effects of ICS/LABA
Local oropharyngeal and laryngeal 
adverse effects
Yes No p
Total case number 54 427
Age (yr) 51.4 ± 16.2 43.7 ± 15.9 0.0011**
Smoking history (pack 
years)
2.1 ± 4.9  6.0 ± 13.0 0.035*
Duration since diagnosis 
(yr)
 4.8 ± 14.6 4.4 ± 9.8 0.21
Daily dose of ICS (μg as 
Fluticasone)
779 ± 328 664 ± 326 0.0087**
FVC (L) 2.9 ± 0.8 3.0 ± 0.9 0.68
FEV1 (L) 2.4 ± 0.7 2.5 ± 0.8 0.48
Peak expiratory fl ow (L/
sec)
6.5 ± 2.1 6.1 ± 2.1 0.24
Data are presented as mean ± standard deviation.
p values were calculated using Mann-Whitney’s U test.
**p < 0.01, *p < 0.05.
two-month period following administration of ICS
LABA. Fifty-four patients had local oropharyngeal
and laryngeal adverse effects (LOLAE) and 20 experi-
enced ‘other’ adverse effects. LOLAE consisted of
hoarseness (n = 19), laryngopharyngeal discomfort
(n = 14), sputum (n = 11), sore throat (n = 5), Candida
thrush (n = 4), stomatitis (n = 2), glossitis (n = 2),
dysgeusia (n = 2), laryngeal dryness (n = 1), and
coughing (n = 1). A complete list of LOLAE and
‘other’ adverse effects is presented in Table 2.
Patients were divided into two groups: those with
(n = 54) and without (n = 20) LOLAE. The patient
characteristics between the groups were then com-
pared and analyzed (Table 3). Patients in the LOLAE
group were significantly older than those in the non-
LOLAE group (51.4 ± 16.2 and 43.7 ± 15.9 years, re-
spectively; p = 0.0011). The prescribed ICS dose was
significantly higher in patients with LOLAE com-
pared to those without (779 ± 328 and 664 ± 326 μg
fluticasone, respectively; p = 0.0087). Regarding
smoking history, patients with LOLAE had a signifi-
cantly lower number of pack-years than those without
LOLAE (2.1 ± 4.9 and 6.0 ± 13.0, respectively; p =
0.0087). No significant differences in duration be-
tween initial diagnosis of asthma and at the time of
this study, FVC, FEV1 and peak expiratory flow were
detected between the two groups.
Next, the association between LOLAE and clinical
parameters was evaluated with Fisher’s exact test
(Table 4). Patients with a history of oral corticoster-
oid administration had a higher incidence of LOLAE
(16.7%) compared to those who had not received oral
corticosteroids (8.4%). A statistically significant asso-
ciation between oral corticosteroid administration
and the development of LOLAE was detected (p =
0.0092, OR 2.16). A statistically significant association
was also detected between a specific type of ICS (FP
or BUD) and the appearance of LOLAE (p = 0.004,
OR 0.32). No significant associations were found be-
tween any other clinical parameters and LOLAE (Ta-
ble 4).
A cross table for the associations between LOLAE
and ICSLABA treatment, grouped by age and smok-
ing history is shown in Table 5. The percentage of pa-
tients experiencing LOLAE increased with increasing
age in never smokers and mild smokers. In contrast,
the incidence of LOLAE in heavy smokers was only
3.3% (n = 30) in patients aged 40-59 and 0% (n = 16) in
those aged 60-79.
DISCUSSION
Clarification of the risk factors of LOLAE for ICS is
important for preventing LOLAE among asthma pa-
tients. In our present retrospective study of 481
asthma patients, we demonstrate that greater age, a
higher dose of ICS, the type of ICS, concurrent use of
oral corticosteroids, and smoking status are signifi-
cantly associated with the occurrence of LOLAE. To
evaluate the mechanisms underlying the association
between LOLAE and the factors identified here, sig-
nificant information regarding the prevention of LO-
LAE will be provided.
Patients of greater age experienced more LOLAE.
This finding is supported by a previous report that
showed older patients (65 years) more frequently
complained of local adverse effects (hoarseness
dysphonia) than those of younger age groups.18 Al-
though it is presently unclear why elderly patients
Horita N et al.
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Table　4　Risk factors for adverse effects of ICS/LABA
Local oropharyngeal and laryngeal adverse effects
p OR
Male/Female 24/206
(11.7%)
30/275
(10.9%)
0.88 1.07
NS/Smokers (ExS + CS) 37/281
(13.2%)
17/200
( 8.5%)
0.14 1.63
Never/Mild/Heavy Smokers 37/281
(13.2%)
16/154
(10.4%)
1/46
( 2.2%)
0.057
CVA/BA 25/207
(12.1%)
29/274
(10.6%)
0.66 1.16
Any previous treatment for asthma (y/n) 15/169
( 8.9%)
39/312
(12.5%)
0.29 0.68
BF/FS  7/143
( 4.9%)
49/338
(13.9%)
0.004** 0.32
History of oral corticosteroid administration (y/n) 27/162
(16.7%)
27/319
( 8.4%)
0.0092*** 2.16
LTRA (y/n) 23/151
(15.2%)
31/330
( 9.4%)
0.060 1.73
Theophylline (y/n) 21/157
(13.4%)
33/324
(10.2%)
0.36 1.36
Short-acting β-agonist (y/n) 5/63
( 7.9%)
49/418
(11.7%)
0.52 0.65
p values were calculated using Fisher’s exact test, with the exception of those for smoking history, which were calculated using the chi 
square test. **p < 0.01,  ***p < 0.001.
ICS/LABA, single inhaled corticosteroids and long-acting beta-agonists; OR, odds ratio; Daily dose of ICS (μg of fl uticasone), budesonide 
dose was converted to half the dose of fl uticasone; NS, Never Smokers; ExS, Ex-Smokers; CS, Current Smokers; Mild Smokers, smokers 
with a smoking history of <20 pack-years; Heavy Smokers, smokers with a smoking history of ≥20 pack-years; CVA/BA, cough-variant asth-
ma/Bronchial asthma; BF/FS, budesonide + formoterol/fl uticasone + salmeterol; LTRA, leukotriene receptor antagonist.
Table　5　Cross table for the association between ICS/LABA and local oropharyngeal and laryngeal adverse effects classifi ed 
by age and smoking history
Smoking history
Age (yr)
Total
≤19 20-39 40-59 60-79 ≥80
Never Smokers  0/14
(0.0%)
 12/127
(9.4%)
10/74
(13.5%)
13/61
(21.3%)
2/5
(40.0%)
 37/281
(13.2%)
Mild Smokers 0/0  3/80
(3.8%)
 6/49
(12.2%)
 7/24
(29.2%)
0/1
( 0.0%)
 16/154
(10.4%)
Heavy Smokers 0/0 0/0  1/30
( 3.3%)
 0/16
( 0.0%)
0/0  1/46
( 2.2%)
Total  0/14
(0.0%)
 15/207
(7.2%)
 17/153
(11.1%)
 20/101
(19.8%)
2/6
(33.3%)
 54/481
(11.2%)
Mild Smokers, smokers with a smoking history of <20 pack-years; Heavy Smokers, smokers with a smoking history of ≥20 pack-years.
display more LOLAE, it has been speculated that eld-
erly people tend to have poor inhalation administra-
tion skills and forget or less frequently wash their
mouth and pharynx after inhalation compared to
younger patients. Furthermore, as elderly people
typically experience age-related declines in immune
function,19 they are expected to have greater risk of
Candida oropharyngitis.
Our analysis revealed that a higher percentage of
patients using FP developed LOLAE compared to
those receiving BUD. This finding is consistent with
a previously reported finding in a systemic review.20
On the other hand, the same author20 demonstrated
that data is available showing no difference in risk of
oral candidiasis between FP and BUD. Although the
reason underlying the identified association between
FP and LOLAE is not clearly demonstrated, it is pos-
sible that the relationship is based on differences be-
tween the particle sizes of FP and BUD. It has been
reported that the smaller particles of ICS reach
Risk Factors for Local Adverse Effects of ICSLABA
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smaller airways, whereas larger particles only reach
the upper airway.21 Thus, as the particle sizes of FP
are larger than those of BUD, FP would have a
greater chance of adhering to the pharynx compared
to BUD. In addition, it has been demonstrated that
lactose combined with fluticasone facilitates deposi-
tion of particles in the upper airway.
A history of oral corticosteroid administration was
also found to be a potential risk factor of LOLAE. In
general, patients with more severe forms of asthma
tend to more frequently receive temporary oral corti-
costeroid treatment for asthma exacerbations. Thus,
the dose of ICS used by patients with a history of oral
corticosteroid administration is likely higher than
those without such a history, and may explain why
this was identified as a risk factor of LOLAE in our
analysis. Interestingly, we identified that patients with
a more extensive smoking history had a lower inci-
dence of LOLAE. The association between smoking
status and the risk of LOLAE of ICSLABA has not
been reported yet. The underlying cause of the rela-
tionship requires careful interpretation. Although,
with the data, it might be logical to consider that
there might be a factor to prevent the development of
LOLAE in smokers, it is more likely that smokers
might not realize or report laryngopharyngeal dis-
comfort or abnormal sensation of the larynx caused
by ICS use, because they are accustomed to
smoking-related troubles of the larynx. Ignoring early
stage adverse events in smoking asthma patients may
lead to the development of more severe adverse ef-
fects that are difficult to treat. Due to this possibility,
doctors should more closely monitor for adverse ef-
fects of ICS when it is prescribed to smokers.
The difference in an occurrence of LOLAE be-
tween patients treated ICSLABA and ICS only might
be useful information for doctors. Although there are
limited published data about the difference in an oc-
currence of LOLAE between patients treated ICS
LABA and ICS, from a clinical investigation, there
were no difference in LOLAE between groups treated
FPsulbutamol and FP only.22
Here, we have provided important information con-
cerning the potential risk factors of LOLAE that
should be applied with care in the clinical treatment
of asthma patients. In particular, doctors should not
discontinue ICSLABA just because a patient has a
risk factor of LOLAE. LOLAE are preventable and re-
versible if they are identified at an early stage. It is
recommended that doctors observe asthma patients
in high-risk groups with extra care and provide infor-
mation concerning the appropriate use of ICSLABA,
including mouth washing technique after inhalation,
especially for elderly patients andor those that re-
ceive high doses of ICSLABA.
In this study, we found that a higher percentage of
patients using FP experienced LOLAE compared to
those receiving BUD. However, as it is generally
known that FP is more powerful (per μg) than BUD,
FP should not be changed to BUD solely based on
the possibility of higher rates of LOLAE in patients
who use FP. In fact, it has been reported that as the
dose of FP increases, so do both the exacerbation
prevention effects and the risk of oral candidiasis.23 It
is essential for doctors to decide which ICSLABA is
most suitable for individual patients based on a wide
range of information, including disease severity, ad-
herence, and risk factors for LOLAE.
In conclusion, greater age, a higher dose of ICS,
and the type of ICS were identified as potential risk
factors of LOLAE based on our retrospective survey.
The apparent lower risk of LOLAE in smokers may
be due to the tendency of these patients to not com-
plain of discomfort even if they experience problems
in the oropharynx and larynx. The identified factors
should be considered in order to prevent LOLAE and
provide optimal treatment to asthmatic patients.
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